Evidence map›Paper›PMID 40849544›Full record

ReviewMolecular psychiatry2025

Above the threshold, beyond the trip: the role of the 5-HT

Adam J Drewko, Ron L P Habets, Tibor M Brunt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Adam J DrewkoMolecular and Biophysical Life Sciences programme, Undergraduate School, Faculty of Science, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0009-0004-7573-4743
Ron L P HabetsPhD, Cell Biology, Neurobiology and Biophysics, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Tibor M BruntPhD, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands. orbit.biomed@gmail.com.ORCID http://orcid.org/0000-0001-5337-9649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serotonergic psychedelics, including the recreationally used psilocybin and LSD, have become promising therapeutic agents for the treatment of treatment-resistant depression. While it is generally agreed that they exhibit their antidepressant effects by inducing rapid and sustained neuroplasticity, the molecular mechanisms responsible are widely debated. In particular, the role of the serotonin 5-HT

Indexed as

Antidepressive AgentsHallucinogensNeuronal PlasticityReceptor, Serotonin, 5-HT2AAnimalsBrainDepressionHumansLysergic Acid DiethylamidePsilocybinSerotonin 5-HT2 Receptor AgonistsAntidepressive AgentsHallucinogensLysergic Acid DiethylamidePsilocybinReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor Agonists

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.